Regulation of human dopamine-like g protein- coupled receptor
OwnerShyam Ramakrishnaninventor
Life of this patent
Estimating the term…
Abstract
Reagents which regulate human dopamine-like G protein-coupled receptor (DA-like GPCR) and reagents which bind to human DA-like GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, obesity and diseases related to obesity, cancer, diabetes, osteoporosis, anxiety, depression, hypertension, migraine, compulsive disorders, schizophrenia, autism, neurodegenerative disorders, such as Alzheimer's disease, Parkinsonism, and Huntington's chorea, and cancer chemotherapy-induced vomiting.
Claims75
An isolated polynucleotide encoding a dopamine-like GPCR polypeptide and being selected from the group consisting of:
- a) a polynucleotide encoding a dopamine-like GPCR polypeptide comprising an amino acid sequence selected form the group consisting of:
- amino acid sequences which are at least about 600% identical to the amino acid sequence shown in SEQ ID NO. 2;
- and
- the amino acid sequence shown in SEQ ID NO. 2.
- b) a polynuecleotide comprising the sequence of SEQ ID NO. 1;
- c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code;
- and
- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a to (d).
A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO. 2.
A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising the steps of:
- culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed;
- and isolating the polypeptide.
A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising the steps of:
- hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO. 1 to nucleic acid material of a biological sample, thereby forming a hybridization complex;
- and
- detecting the hybridization complex.
A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising the steps of:
- contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex;
- and
- detecting the reagent-polypeptide complex.
A method of screening for agents which can regulate the activity of a dopamine-like GPCR protein, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected form the group consisting of:
- (1) amino acid sequences which are at least about 60% identical to the amino acid sequence shown in SEQ ID NO. 2 and (2) the amino acid sequence shown in SEQ ID NO. 2;
- and
- detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the dopamine-like GPCR protein.
A method of screening for agents which regulate an activity of a human dopamine-like GPCR protein, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 60% identical to the amino acid sequence shown in SEQ ID NO. 2 and (2) the amino acid sequence shown in SEQ ID NO. 2;
- and
- detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human dopamine-like GPCR protein, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human dopamine-like GPCR protein.
A method of screening for agents which regulate an activity of a human dopamine-like GPCR protein, comprising the steps of:
- contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO. 1;
- and
- detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human dopamine-like GPCR protein.
A method of reducing activity of a human dopamine-like GPCR protein, comprising the step of:
- contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO. 1, whereby the activity of a human dopamine-like GPCR protein is reduced.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO. 1;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2;
- and
- a pharmaceutically acceptable carrier.
A method of treating dopamine-like GPCR disorder, comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a reagent that inhibits a function of a human dopamine-like GPCR protein, whereby symptoms of the dopamine-like GPCR disorder are ameliorated.
Dependencies are inferred from the claim text.